GenTrust’s Alnylam Pharmaceuticals ALNY Stock Holding History

GenTrust’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-695	Closed	-$276K	–	285
2025 Q4	$276K	Buy	+695	New	+$308K	0.01%	220

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GenTrust's ALNY Position: Q1 2026 in Review

GenTrust sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 695 shares — an estimated $276K sold.

GenTrust first reported a position in ALNY in Q4 2025 and held it in 1 quarter. The position peaked at $276K in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

GenTrust reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
GenTrust sold 695 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $276K.
GenTrust first reported a position in Alnylam Pharmaceuticals in Q4 2025 and held it in 1 quarter.
GenTrust's Alnylam Pharmaceuticals position peaked at $276K in Q4 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on GenTrust's 13F filing for Q1 2026, filed 27 Apr 2026.